Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Director · President and CEO | May 13, 2026 | May 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Karyopharm Therapeutics Inc.
Report date May 13, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 269,747 |
Ending reported balance
After 2026-05-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-13 · Grant · Acquired 4,920 · Balance 271,950 F1: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026. Row 2 · 2026-05-14 · Sale · Disposed 2,203 · Balance 269,747 F2: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026.
F2: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
bluebird bio, Inc.
Report date May 30, 2025 · Filed June 03, 2025
Section 16 reporting ended · disclosed 2025-06-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-06-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-30 · Other · Disposed 155 · Balance 1,323 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Row 2 · 2025-06-02 · Disposition to issuer · Disposed 1,323 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F4: (Continued from footnote 3) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price").
F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive
F4: (Continued from footnote 3) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2023 Filed Jan 5, 2023 23:16 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,922 | $3.27 | $12,824.94 |
DisclosureSEC source: 0001209191-23-002052 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,605 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 22:00 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,490 | $5.17 | $18,043.30 |
DisclosureSEC source: 0001209191-22-060041 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 612,527 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 23:19 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,493 | $4.54 | $15,858.22 |
DisclosureSEC source: 0001209191-22-056152 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 616,017 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| October 04, 2022 Filed Oct 5, 2022 20:12 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,488 | $5.87 | $20,474.56 |
DisclosureSEC source: 0001209191-22-052726 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 619,510 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 12:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 3,463 | $5.23 | $18,111.49 |
DisclosureSEC source: 0001209191-22-049255 · doc4.xml · nonDerivative · entry 2 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 622,998 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 12:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 16 | $5.26 | $84.10 |
DisclosureSEC source: 0001209191-22-049255 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,461 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,314 | $4.48 | $10,366.72 |
DisclosureSEC source: 0001209191-22-044561 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,477 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 08, 2022 Filed Jul 11, 2022 20:18 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,115 | $5.18 | $10,947.66 |
DisclosureSEC source: 0001209191-22-041774 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628,791 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 20:23 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 2,542 | $5.76 | $14,642.43 |
DisclosureSEC source: 0000899243-22-021477 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,906 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 04, 2022 Filed May 5, 2022 20:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 27,869 | $6.23 | $173,545.84 |
DisclosureSEC source: 0001209191-22-027344 · doc4.xml · nonDerivative · entry 2 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 633,448 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 04, 2022 Filed May 5, 2022 20:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 633 | $6.26 | $3,963.47 |
DisclosureSEC source: 0001209191-22-027344 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 661,317 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 20:14 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 360,000 | $0.00 Strike: $10.33 | $0.00 |
DisclosureSEC source: 0001209191-22-014619 · doc4.xml · derivative · entry 2 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2032-02-27 F2 · derivative.exercise_date: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 20:14 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 288,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014619 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 661,950 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023. Read SEC document |
| May 03, 2021 Filed May 5, 2021 01:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 559,800 | $0.00 Strike: $9.44 | $0.00 |
DisclosureSEC source: 0001209191-21-030166 · doc4.xml · derivative · entry 2 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 559,800 Underlying: Common Stock · 559,800 shares Expires 2031-05-02 F2 · derivative.exercise_date: This option was granted on May 3, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on May 3, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 03, 2021 Filed May 5, 2021 01:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 373,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030166 · doc4.xml · nonDerivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373,200 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 25% of the shares on May 3, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 21, 2020 Filed May 26, 2020 20:25 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 16,400 | $0.00 Strike: $19.11 | $0.00 |
DisclosureSEC source: 0001209191-20-032013 · doc4.xml · derivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2030-05-20 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 21, 2021, provided that the reporting person continues to serve as a director of the issuer through such date. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 21:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $26.12 | $0.00 |
DisclosureSEC source: 0001209191-20-017361 · doc4.xml · derivative · entry 1 Paulson Richard A. · CIK 0001804460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-03-04 F1 · derivative.exercise_date: This option was granted on March 5, 2020. The shares underlying this option vest as to one-third (1/3) of the shares on March 5, 2021 and as to the remaining two-thirds (2/3) of the shares in 24 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.